title: MCP-1 promoter variant -362C associated with protection from pulmonary tuberculosis in Ghana, West Africa.
abstract: Current endeavour focuses on human genetic factors that contribute to susceptibility to or protection from tuberculosis (TB). Monocytes are crucial in containing Mycobacterium tuberculosis infection, and the monocyte chemoattractant protein-1 (MCP-1) cytokine plays a role in their recruitment to the site of infection. The G allele of the MCP-1 promoter polymorphism at position -2581 relative to the ATG transcription start codon has been described to be associated in Mexican and Korean TB patients with increased susceptibility to TB. We genotyped this and additional MCP-1 variants in sample collections comprising more than 2000 cases with pulmonary TB and more than 2300 healthy controls and 332 affected nuclear families from Ghana, West Africa, and more than 1400 TB patients and more than 1500 controls from Russia. In striking contrast to previous reports, MCP-1 -2581G was significantly associated with resistance to TB in cases versus controls [odds ratio (OR) 0.81, corrected P-value (P(corr)) = 0.0012] and nuclear families (OR 0.72, P(corr) = 0.04) and not with disease susceptibility, whereas in the Russian sample no evidence of association was found (P = 0.86). Our and other results do not support an association of MCP-1 -2581 with TB. In the Ghanaian population, eight additional MCP-1 polymorphisms were genotyped. MCP-1 -362C was associated with resistance to TB in the case-control collection (OR 0.83, P(corr) = 0.00017) and in the affected families (OR 0.7, P(corr) = 0.004). Linkage disequilibrium (LD) and logistic regression analyses indicate that, in Ghanaians, the effect results exclusively from the MCP-1 -362 variant, whereas the effect of -2581 may in part be explained by its LD with -362.
authors.affiliation: Department of Molecular Medicine, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Thye
authors.forename: Sergey
authors.initials: S
authors.lastname: Nejentsev
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Intemann
authors.forename: Edmund N
authors.initials: EN
authors.lastname: Browne
authors.forename: Margaret Amanua
authors.initials: MA
authors.lastname: Chinbuah
authors.forename: John
authors.initials: J
authors.lastname: Gyapong
authors.forename: Ivy
authors.initials: I
authors.lastname: Osei
authors.forename: Ellis
authors.initials: E
authors.lastname: Owusu-Dabo
authors.forename: Lauren R
authors.initials: LR
authors.lastname: Zeitels
authors.forename: Florian
authors.initials: F
authors.lastname: Herb
authors.forename: Rolf D
authors.initials: RD
authors.lastname: Horstmann
authors.forename: Christian G
authors.initials: CG
authors.lastname: Meyer
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D018932:Chemokine CCL2 / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D005869:Ghana / Q000453:epidemiology; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D012426:Russia / Q000453:epidemiology; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology / Q000235:genetics*
chemical_list: C111835:CCL2 protein, human; D018932:Chemokine CCL2